Post-hoc Analysis of Serum TTR

• Blood samples from participants in ATTRibute-CM were taken  to measure mean change in serum TTR levels from baseline to month 30.
• Participants were allowed to receive tafamidis 12 months after randomisation. At month 30, there was, on average, a 42% difference in serum TTR between participants in the placebo arm receiving tafamidis (n = 35), and those receiving acoramidis (n = 234).

PP-BEY-IE-0042-1   |   November 2025

^{▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professional are asked to report any suspected adverse reactions.}